PMID: 7036709Feb 18, 1982Paper

Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: report of a cooperative clinical trial

The American Journal of Cardiology
W E StraussW Shapiro

Abstract

Sixty-three patients completed a multicenter 10 week, double-blind, parallel group protocol evaluating the efficacy of diltiazem versus placebo with respect to rate of attacks of angina, nitroglycerin consumption and duration of treadmill exercise. An additional 36 patients were evaluated for drug safety. A 4 week placebo lead-in phase was followed by a 2 week dose titration period and two treatment evaluation periods of 2 weeks each. Both diltiazem and placebo were associated with a significant reduction in weekly frequency of angina from the baseline rate. Intergroup comparison disclosed a significantly greater reduction for the patients receiving diltiazem than for those receiving placebo. A similar reduction was noted for nitroglycerin consumption. Total exercise duration at week 10 was statistically greater in patients treated with diltiazem. Diltiazem was well tolerated. No abnormalities in hematologic profiles or in routine serum chemistry values were observed; electrocardiographic P-R and QRS intervals were unaffected. Adverse effects that could have been related to drug administration were reported in 11 patients who received diltiazem and in 12 patients who received placebo. Of the 17 episodes in the diltiazem group o...Continue Reading

References

Jan 1, 1978·Circulation·J E Muller, S J Gunther
Nov 8, 1979·The New England Journal of Medicine·F H Meyers
Jan 1, 1980·British Journal of Clinical Practice. Supplement·H YasueS Tanaka
Jan 1, 1981·The American Journal of Cardiology·K F Hossack, R A Bruce

❮ Previous
Next ❯

Citations

Sep 1, 1985·Postgraduate Medical Journal·D Wheatley
Jul 1, 1984·British Heart Journal·J KennyD E Jewitt
Aug 1, 1985·Mayo Clinic Proceedings·C ShubM D McGoon
Feb 1, 1990·Mayo Clinic Proceedings·C Shub
Jan 25, 1985·The American Journal of Cardiology·S E EpsteinD R Rosing
Dec 1, 1989·The American Journal of Cardiology·W P KlinkeE E Dempsey
Jan 1, 1986·The American Journal of Cardiology·M JoyalC J Pepine
Jul 1, 1985·The American Journal of Cardiology·C L WolfeM D Winniford
Aug 1, 1985·Current Problems in Cardiology·D McCallR A O'Rourke
Jul 1, 1993·International Journal of Cardiology·R SteffensenS Haunsø
Jan 1, 1986·American Heart Journal·M JoyalC J Pepine
Sep 1, 1984·The American Journal of Cardiology·M J O'HaraE B Raftery
Oct 1, 1984·The American Journal of Cardiology·P MaterneH E Kulbertus
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Steven A Claas, Stephen P Glasser
Dec 1, 1988·Journal of the American College of Cardiology·W P KlinkeM Grace
Apr 1, 1983·Journal of the American College of Cardiology·V Bala SubramanianE B Raftery
Dec 1, 1983·Journal of the American College of Cardiology·B S LindenbergM D Klein
Jan 25, 1985·The American Journal of Cardiology·M B LeonS E Epstein
Mar 15, 1995·The American Journal of Cardiology·C NadeauL Larivière
Sep 1, 2016·Cardiovascular Drugs and Therapy·Isaac PascualPablo Avanzas
Oct 7, 1982·The New England Journal of Medicine·K F Hossack
Dec 23, 1982·The New England Journal of Medicine·E Braunwald
Jun 1, 1986·Journal of Clinical and Hospital Pharmacy·M J Kendall, J V Okopski
Apr 1, 1985·Australian and New Zealand Journal of Medicine·K F HossackR A Bruce
Jan 1, 1988·Cardiovascular Drugs and Therapy·E ThaulowJ Ross
Jan 1, 1982·International Journal of Cardiology·M H Crawford
Jan 1, 1982·International Journal of Cardiology·A F Parisi
May 13, 2014·Therapeutic Advances in Cardiovascular Disease·Monika Garg, Deepa Khanna
Jan 1, 1986·European Journal of Clinical Pharmacology·A GordinP Männistö

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.